Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cage TA et al. - Postoperative administration of enoxaparin following meningioma resection does not increase the risk of intracranial hematoma though enoxaparin administration may slightly decrease the incidence of post-surgical thromboembolic events. Due to study design and power, authors were not able to demonstrate DVT/VTE reduction with statistical significance.

Related Articles

Hypermethylation and Transcriptional Downregulation of the TIMP3 Gene Is Associated with Allelic Loss on 22q12.3 and Malignancy in Meningiomas
Brain Pathology, 11/20/09    Relevance Score: 91%

A meningioma of the scalp that might have developed from a rudimentary meningocele
Clinical and Experimental Dermatology, 10/16/09    Relevance Score: 90%

Jugular fossa meningioma: Presentation and treatment options
ENT Journal, 10/21/09    Relevance Score: 89%

Diagnosis and Treatment of the Primary Malignant Meningioma in Mediastinum: A Case Report
Southern Medical Journal, 11/10/09    Relevance Score: 88%

Radiation-induced meningiomas: A shadow in the success story of childhood leukemia
Neuro-Oncology, 10/06/09    Relevance Score: 88%

Today in Coagulation/Bleeding Dz...keeping you current

Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study
Acta Haematologica, 12/04/09

Hematological Issues in Critically Ill Patients with Cancer
Critical Care Clinics, 12/04/09

Pharmacokinetics and safety of fibrinogen concentrate
Journal of Thrombosis and Haemostasis, 12/03/09

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address